患有致癌突变的晚期肺癌患者应入住重症监护病房。 - Suppr

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

作者信息

Toffart Anne-Claire, Dhalluin Xavier, Girard Nicolas, Chouaid Christos, Audigier-Valette Clarisse, Duruisseaux Michaël, Mennecier Bertrand, Parrot Antoine, Fournel Pierre, Moro-Sibilot Denis, Timsit Jean-François

机构信息

Grenoble University 1 U 823, A Bonniot Institute, J Fourier University, Rond-point de la Chantourne, 38706, La Tronche Cedex, France,

出版信息

Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4.

DOI:10.1007/s00134-014-3535-x

PMID:25366122

Abstract

摘要

相似文献

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4.

Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.

Cancer Med. 2019 Jun;8(6):2858-2866. doi: 10.1002/cam4.2183. Epub 2019 Apr 24.

Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.

Ann Oncol. 2013 May;24(5):1319-25. doi: 10.1093/annonc/mds626. Epub 2012 Dec 30.

Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer.

J Exp Clin Cancer Res. 2013 May 20;32(1):29. doi: 10.1186/1756-9966-32-29.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by Fusions.

Clin Cancer Res. 2020 Jun 15;26(12):2932-2945. doi: 10.1158/1078-0432.CCR-19-3321. Epub 2020 Mar 2.

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Cancer Treat Rev. 2018 Dec;71:47-58. doi: 10.1016/j.ctrv.2018.10.006. Epub 2018 Oct 15.

Predictive markers in lung cancer: a few hints for the practicing pathologist.

Pathologica. 2018 Mar;110(1):29-38.

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.

J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16.

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.

J Thorac Oncol. 2015 May;10(5):778-783. doi: 10.1097/JTO.0000000000000487.

引用本文的文献

Severe hemoptysis associated with lung cancer in the ICU: recurrence and outcome.

Ann Intensive Care. 2025 Mar 20;15(1):33. doi: 10.1186/s13613-025-01421-7.

[Palliative aspects in clinical acute and emergency medicine as well as intensive care medicine : Consensus paper of the DGIIN, DGK, DGP, DGHO, DGfN, DGNI, DGG, DGAI, DGINA and DG Palliativmedizin].

Med Klin Intensivmed Notfmed. 2023 Dec;118(Suppl 1):14-38. doi: 10.1007/s00063-023-01016-9. Epub 2023 Jun 7.

Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study.

BMC Pulm Med. 2022 Jun 24;22(1):245. doi: 10.1186/s12890-022-02042-7.

Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment.

Ann Intensive Care. 2021 Dec 24;11(1):182. doi: 10.1186/s13613-021-00968-5.

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation.

Biomedicines. 2021 Oct 8;9(10):1416. doi: 10.3390/biomedicines9101416.

[Not Available].

Rev Malad Respir Actual. 2021 Sep;13(2):2S244-2S251. doi: 10.1016/S1877-1203(21)00116-6. Epub 2021 Oct 11.

Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation.

Thorac Cancer. 2020 Sep;11(9):2672-2680. doi: 10.1111/1759-7714.13604. Epub 2020 Aug 6.

The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Intensive Care Med. 2017 Sep;43(9):1366-1382. doi: 10.1007/s00134-017-4884-z. Epub 2017 Jul 19.

Focus on immunocompromised patients.

Intensive Care Med. 2017 Sep;43(9):1415-1417. doi: 10.1007/s00134-017-4857-2. Epub 2017 Jun 9.

Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit.

J Thorac Dis. 2016 Nov;8(11):E1455-E1461. doi: 10.21037/jtd.2016.11.110.

本文引用的文献

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.

J Thorac Oncol. 2013 Feb;8(2):250-3. doi: 10.1097/JTO.0b013e3182746772.

Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.

J Thorac Oncol. 2013 Jan;8(1):e1-2. doi: 10.1097/JTO.0b013e3182762812.

Use of intensive care in patients with nonresectable lung cancer.

Chest. 2011 Jan;139(1):101-8. doi: 10.1378/chest.09-2863. Epub 2010 Jul 15.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献